Link Pharma Chem Ltd has filed a regulatory disclosure with BSE Limited regarding the transmission of equity shares following the demise of one of its promoters. The filing, made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, details the transfer of a significant shareholding within the promoter group.

Share Transmission Details

The disclosure pertains to the transmission of 92,808 equity shares, representing 2.09% of the company's total shareholding. The shares were transmitted following the sad demise of Mr. Shriniwas Vasantrao Thakur, who was one of the promoters of Link Pharma Chem Ltd. The transmission was made to his spouse, Mangala Shriniwas Thakur, through an off-market transfer process.

Shareholding Pattern Changes

According to the regulatory filing, the acquirer's shareholding position has changed significantly due to this transmission. Before the acquisition, Mangala Shriniwas Thakur held no shares in the company. Post-transmission, she now holds 92,808 equity shares, representing 2.09% of the total voting capital.

Company's Share Capital Structure

The filing reveals that Link Pharma Chem Ltd's total equity share capital stands at ₹44,405,680.00, divided into 4,440,568 equity shares of ₹10.00 each. This capital structure remains unchanged following the share transmission, as it represents an internal transfer within the promoter group rather than a fresh issue of shares.

Regulatory Compliance

The disclosure was filed in compliance with SEBI regulations governing substantial acquisition of shares and takeovers. Mangala Shriniwas Thakur, now classified as belonging to the promoter group, submitted the required documentation to BSE Limited's Department of Corporate Services. The filing includes all necessary details as prescribed under the regulatory framework, ensuring transparency in shareholding changes within the promoter group.

Link Pharma Chem Limited , a chemicals manufacturer, has released its unaudited financial results for the second quarter and first half of the fiscal year 2026, along with an announcement of a key personnel change.

Financial Performance

The company reported a mixed financial performance for the quarter ended September 30, 2025:

For the half-year period:

The company's revenue from operations saw a decline in the second quarter compared to the same period last year. However, the half-yearly revenue showed a slight increase.

Management Change

The Board of Directors has accepted the resignation of Ms. Khushbu Prakashbhai Patel from her position as Company Secretary and Compliance Officer. Her resignation will be effective from December 16, 2025. The company stated that Ms. Patel is leaving to pursue better prospects outside the organization.

Company Overview

Link Pharma Chem Limited operates in the manufacture and sale of chemicals segment.

Financial Trends

Looking at the broader financial picture:

The company has shown some improvement in its net loss position and operating profit margin compared to the previous fiscal year, despite a decrease in annual revenue.